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Abstract
Although neuraminidase inhibitors are active against most 2009–
2010 pandemic inﬂuenza A (H1N1) swine-origin strains, sporadic
cases of oseltamivir resistance have been described. Since April
2009, 54 cases of oseltamivir-resistant H1N1 swine-origin have
been reported in the USA (http://www.cdc.gov/ﬂu/weekly/;
accessed 1 February 2010). Approximately 1.4% of tested iso-
lates are oseltamivir resistant. We report a patient with an
underlying hematological malignancy who was hospitalized with
inﬂuenza A (H1N1) swine-origin and whose strain developed
oseltamivir resistance during therapy.
Keywords: H1N1, immunocompromised, inﬂuenzaA, oseltamivir,
resistance
Original Submission: 14 February 2010; Accepted: 1 March
2010
Editor: D. Raoult
Article published online: 10 March 2010
Clin Microbiol Infect 2010; 16: 1576–1578
10.1111/j.1469-0691.2010.03212.x
Corresponding author: P. A. Chan, Division of Infectious Disease,
Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA
E-mail: pchan@lifespan.org
A 26-year-old female with pre-B acute lymphocytic leukaemia
was admitted to our hospital on November 18, 2009 for
re-induction chemotherapy. She was started on high-dose
cytarabine, L-asparaginase, acyclovir and trimethoprim-sulpha-
methoxazole. On admission, her absolute neutrophil count
(ANC) was 800 cells/lL. On hospital day 3, she developed a
nonproductive cough and had a temperature of 102.6F with
an ANC of 300 cells/lL. She was started on vancomycin,
cefepime and oseltamivir 75 mg twice daily. One of two
blood cultures grew a-haemolytic streptococci. A nasopha-
ryngeal swab sent for respiratory viral panel testing (xTAG
RVP; Luminex Corp., Austin, TX, USA) revealed inﬂuenza A
(H1N1), nonsubtypeable probable swine-origin and rhinovi-
rus (Table 1). On hospital day 8, she had a temperature of
103.6F and posaconazole and meropenem were added, osel-
tamivir was continued, and cefepime was stopped. Chest
computed tomography (CT) demonstrated patchy airspace
disease in the right lung consistent with pneumonia. Fevers
continued and several blood and urine cultures were nega-
tive. A bronchoscopy performed on hospital day 11 revealed
negative cultures for aerobic, anaerobic, and acid-fast









3 NP Inﬂuenza A H1N1,
swine-origin
Inﬂuenza A Negative
11 Bronchoscopy NA Inﬂuenza A Positive
17 NP Inﬂuenza A H1N1,
swine-origin
Inﬂuenza A Positive
20 NP Negative NA NA
NP, nasopharyngeal; NA, not available; RVP, respiratory viral panel.
aResistance testing performed on hospital day 17 returned on hospital day 23.
Isolates from hospital day 3 and 11 were subsequently tested for the H275Y
mutation (ViraCor, Lee’s Summit, MO, USA).
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bacteria, legionella and fungi. Direct-ﬂuorescent antibody
testing for Pneumocystis jiroveci was negative. A viral culture
derived from the bronchoscopy specimen grew inﬂuenza A
(H1N1) swine-origin. The patient continued to have daily
fever in the setting of prolonged neutropenia, and lipid-formu-
lation amphotericin B (Abelcet; Enzon Pharmacueticals,
Bridgewater, NJ, USA) was added with discontinuation of the
posaconazole. Urine legionella antigen and galactomannan
assays were negative. On hospital day 14, the patient was
transferred to the intensive care unit for refractory hypoten-
sion. She developed diarrhoea and doxycycline and metroni-
dazole were added. The patient stabilized within 24 h and
was transferred back to a medical unit. On hospital day 17, a
nasopharyngeal swab again revealed H1N1, as well as rhino-
virus, despite 13 days of oseltamivir. A repeat chest CT scan
showed worsening right lung inﬁltrates. A concern for osel-
tamivir-resistance was raised. The patient was changed to
zanamivir, two inhalations twice daily, and a nasopharyngeal
swab was sent for resistance testing (ViraCor, Lee’s Summit,
MO, USA). Fevers continued. Clostridium difﬁcile toxin testing
was negative. Doxycycline and metronidazole were discon-
tinued and amphotericin B was changed to posaconazole. A
transthoracic echocardiogram performed on hospital day 17
revealed severe left ventricular dysfunction with an ejection
fraction of 20%. An echocardiogram in 2008 was normal. It
was unclear whether the cardiomyopathy was secondary to
chemotherapy (cumulative lifetime anthracycline dose of
317 mg) or viral myocarditis. A nasopharyngeal swab sent
for respiratory viral panel testing on hospital day 20 was neg-
ative. On hospital day 23, a nasopharyngeal swab performed
on hospital day 17 was found to be positive for oseltamivir-
resistant inﬂuenza A with the H275Y mutation. Zanamivir
had been discontinued after 5 days. A repeat bedside trans-
thoracic echocardiogram demonstrated moderate pericardial
effusion without tamponade and a left ventricular ejection
fraction recovered to 65%. Despite aggressive therapy, she
died on hospital day 40. An autopsy was not performed.
After her death, we performed resistance testing on a stored
sample of the initial inﬂuenza strain isolated on hospital day
3, which was sensitive to oseltamivir. Additional testing was
also performed on the bronchoscopy specimen from hospital
day 11, which demonstrated that resistance to oseltamivir
had developed after 8 days of oseltamivir therapy.
To our knowledge, this is the ﬁrst case of oseltamivir-
resistant, swine-origin inﬂuenza A (H1N1) associated with a
fatal outcome. Despite widespread use of oseltamivir for
prophylaxis and treatment during the 2009–2010 inﬂuenza
season, resistance to this agent is relatively rare [1–4,5–7]. In
the USA, 42 of 52 individuals with resistance had docu-
mented exposure to oseltamivir (http://www.cdc.gov/ﬂu/
weekly/; accessed 1 February 2009), suggesting that most
cases of resistance in the USA developed under selective
pressure to the drug. Resistance developed during oseltami-
vir treatment in our patient who was receiving 75 mg twice
daily. The recent literature suggests that an increased dose
of 150 mg twice daily may be preferable for critically ill
patients [8]. The most commonly reported mutation associ-
ated with oseltamivir-resistant H1N1 swine-origin is the
H275Y mutation [9–12]. Resistance may develop more com-
monly in immunocompromised patients [6], particularly those
with haematological malignancies [2,13]. Mortality from sea-
sonal inﬂuenza in immunocompromised patients is high [12].
However, we are unaware of reported cases involving osel-
tamivir-resistant, H1N1 swine-origin associated with death,
including immunocompromised patients. Resistance testing
should be carried out in H1N1 swine-origin infected, immu-
nocompromised patients who fail to respond appropriately to
antiviral therapy. Higher dosing of oseltamivir at 150mg twice
a day should also be considered in these patients.
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